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ScienceDirectThe clinical success of Adcetris1 (brentuximab vedotin) and
Kadcyla1 (ado-trastuzumab emtansine) has sparked clinical
development of novel ADCs. These powerful anti-cancer
agents are designed to allow specific targeting of highly
potent cytotoxic agents to tumor cells while sparing healthy
tissues. Despite the use of tumor-specific antibodies, the
emerging clinical data with ADCs indicates that adverse
effects frequently occur before ADCs have reached their
optimal therapeutic dose, resulting in a relatively narrow
therapeutic window. This review summarizes the therapeutic
window of ADCs currently in clinical development, along
with some strategies that may help to widen the
window.
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Introduction
The prospects for development of antibody-drug conju-
gates (ADCs) as effective, well-tolerated anti-cancer ther-
apeutics have changed dramatically since the approval of
Adcetris1 (brentuximab vedotin) in 2011 and Kadcyla1
(ado-trastuzumab emtansine) in 2013. Currently, over
50 different ADCs are in clinical development, the ma-
jority consisting of IgG1 antibodies conjugated with po-
tent microtubule inhibitors, either derivatives of
maytansine, or auristatins which are analogs of dolastatin
10 (Table 1). These compounds display cytotoxicity at
1000-fold lower concentration than standard chemo-
therapeutic agents [1], which makes them too toxic for
systemic treatment [2,3]. By conjugating these potent
cytotoxins to tumor-specific antibodies, their cytotoxic
effect can be concentrated at tumor cells. At the same
time, the pharmacokinetic profile of the toxins willCurrent Opinion in Immunology 2016, 40:14–23 improve upon conjugation to antibodies, giving to the
small molecular weight cytotoxin the long half-life of an
immunoglobulin. Notwithstanding the clinical success of
brentuximab vedotin and ado-trastuzumab emtansine,
the development for therapeutic use of most ADCs is
still hampered by a relatively narrow therapeutic window.
Although tumor-specific antibodies allow enrichment of
cytotoxic payloads in tumors, adverse effects frequently
occur before ADCs have reached their optimal therapeu-
tic dose, which may limit their clinical response. In this
short review, we have summarized available data from
clinical and preclinical studies to assess the therapeutic
window of ADCs. In addition, this review will discuss
three aspects of ADC design, that may be important
factors in helping to increase the therapeutic window
of ADCs (Figure 1): first, the target selection require-
ments for ADC development; second, the interaction of
ADCs with the immune system; third, the development
of novel DNA damaging agents with low picomolar
efficacy.
Therapeutic window of ADCs in clinical
development
The majority of ADCs in clinical development make use
of tubulin-targeting antimitotic agents. These agents
(maytansinoids and auristatins [4]) bind to the vinca-
binding domain of tubulin, thereby interfering with mi-
crotubule dynamics and causing cell cycle arrest in the
G2/M phase [5]. Table 1 shows that antibodies coupled
with the maytansinoids DM1 or DM4 typically reach a
maximum tolerated dose (MTD) in humans in the range
of 110–240 mg/m2 (about 3–6.5 mg/kg) [6–8]. For anti-
bodies conjugated with the dolastatin 10 analogs, mono-
methyl auristatin E or F (MMAE; MMAF), MTDs were
established at doses around 80–110 mg/m2 (about 2–3 mg/
kg) [9–11]. It is not known what dose would be required to
achieve optimal therapeutic efficacy in the clinic. How-
ever, some lessons may be drawn from preclinical studies
in murine xenograft models. Given that both mice and
humans have about 40–43 mL plasma per kg of body
weight [12], and assuming that pharmacokinetic proper-
ties are approximately similar in mice and human, thera-
peutic activity should be observed at similar dose levels in
mice and human. Thus, ADCs conjugated with maytan-
sinoids or auristatins should show preclinical activity at
doses at or below 3–6.5 mg/kg and 2–3 mg/kg, respective-
ly. Preclinical studies in mice suggest that such doses
levels are often suboptimal. For example, ado-trastuzu-
mab emtansine has an MTD of 3.6 mg/kg in humans [6].
In preclinical models of breast cancer, ado-trastuzumabwww.sciencedirect.com
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Table 1
Overview of ADCs in clinical development. The last column shows the maximum tolerated dose in mg/kg, as well as the reported dose-
limiting toxicities
Drug names Sponsor Phase Indication Target Payload Linker Bystander MTD mg/kg
Adcetris,
brentuximab
vedotin,
SGN-35
Seattle
Genetics, Inc.
Approved Hematological CD30 MMAE VC Yes 1.8 [9]
thrombocytopenia,
neutropenia
Kadcyla, T-DM1,
trastuzumab
emtansine,
PRO132365
Genentech, Inc. Approved Solid HER2 DM1 SMCC No 3.6 [6]
thrombocytopenia,
neutropenia
Inotuzumab
ozogamicin,
CMC-544
Pfizer 3 Hematological CD22 Calicheamicin Hydrazone
acetyl
butyrate
Yes 0.05 [52]
thrombocytopenia,
neutropenia
Gemtuzumab
ozogamicin
Pfizer 2 Hematological CD33 Calicheamicin Hydrazone
Acetyl
Butyrate
Yes 0.25 [53,54] no
DLTa
ABT-414 Abbvie 2 Solid EGFR MMAF MC No 3.0 [55] ocular
toxicity
Glembatumumab
vedotin,
CDX-011,
CR011-
vcMMAE
Celldex
therapeutics
2 Solid gpNMB MMAE VC Yes 1.9 [16]
neutropenia,
rash
IMMU-130,
labetuzumab
govitecan,
labetuzumab-
SN-38,
hMN14-SN38
Immunomedics,
Inc.
2 Solid CEACAM5 SN-38 CL2A Yes 6–10 [56]
neutropenia,
typhlitis, nausea
IMMU-132,
sacituzumab
govitecan,
hrS7-SN-38
Immunomedics,
Inc.
2 Solid TROP2,
EGP1
SN-38 CL2A Yes 8–10 [57]
neutropenia
Lifastuzumab
vedotin,
NaPi2b ADC,
RG7599,
DNIB0600A
Genentech, Inc. 2 Solid NaPi2b MMAE VC Yes 2.4 [26] dyspnea
Indusatumab
vedotin,
MLN0264,
5F9-vcMMAE
Millennium
Pharmaceuticals,
Inc.
2 Solid GCC MMAE VC Yes 1.8 [10]
neutropenia
Polatuzumab
vedotin,
RG7596,
DCDS4501A
Genentech, Inc. 2 Hematological CD79b MMAE VC Yes 2.4 [29]
neutropenia
Pinatuzumab
vedotin,
RG7593,
DCDT2980S
Genentech, Inc. 2 Hematological CD22 MMAE VC Yes 2.4 [28]
neutropenia
PSMA ADC Progenics
Pharmaceuticals,
Inc
2 Solid PSMA MMAE VC Yes 2.5 [25]
neutropenia,
liver toxicity
SAR3419,
coltuximab
ravtansine
ImmunoGen, Inc. 2 Hematological CD19 DM4 SPDB Yes 4.3 [7] ocular
toxicity
BMS-986148 Bristol-Myers
Squibb
1, 2 Solid MSLN Unknown Unknown Unknown
BT-062,
Indatuximab
ravtansine
Biotest
Pharmaceuticals
Corporation
1, 2 Hematological CD138,
Syndecan1
DM4 SPDB Yes 2.7 [58]
mucositis,
anemia
IMMU-110,
milatuzumab
doxorubicin,
hLL1-DOX
Immunomedics,
Inc.
1, 2 Hematological CD74 Doxorubicin Hydrazone Yes >16 [59] no
DLT reported
www.sciencedirect.com Current Opinion in Immunology 2016, 40:14–23
16 Special section: New concepts in antibody therapeutics
Table 1 (Continued )
Drug names Sponsor Phase Indication Target Payload Linker Bystander MTD mg/kg
MLN2704 Millennium
Pharmaceuticals,
Inc
1, 2 Solid PSMA DM1 SPP Yes No MTD
reported
neutropenia,
neuropathy [60]
SAR408701 Sanofi 1, 2 Solid CEACAM5 DM4 SPDB Yes
SC16LD6.5,
rovalpituzumab
tesirine
Stem CentRx, Inc. 1, 2 Solid Delta-like
protein 3
(DLL3)
D6.5 (PBD) VA Yes 0.2 [49,50]
thrombocytopenia,
capillary leak
syndrome
ABBV-399 Abbvie 1 Solid Unknown Unknown Unknown Unknown
AGS-16C3F Astellas Pharma
Inc.; Agensys,
Inc.
1 Solid ENPP3 MMAF MC No 1.8 [23]
ocular toxicity,
thrombocytopenia
ASG-22ME Astellas Pharma
Inc.; Agensys,
Inc.
1 Solid Nectin4 MMAE VC Yes
AGS67E Agensys, Inc. 1 Hematological CD37 MMAE VC Yes
AMG 172 Amgen 1 Solid CD27 DM1 Non-
cleavable
No
AMG 595 Amgen 1 Solid EGFRvIII DM1 SMCC No
AGS-15E Agensys, Inc. 1 Solid SLTRK6 MMAE VC Yes
BAY1129980 Bayer 1 Solid C4.4a Unknown Unknown Unknown
BAY1187982 Bayer 1 Solid FGFR2 Unknown Unknown Unknown
BAY94-9343,
anetumab
ravtansine
Bayer 1 Solid Mesothelin DM4 SPDB Yes 6.5 [22] ocular
toxicity
GSK2857916 GlaxoSmithKline 1 Hematological BCMA MMAF MC No
Humax-TF-ADC,
tisotumab
vedotin
Genmab 1 Solid TF MMAE VC Yes TBD [61]
IMGN289 ImmunoGen, Inc. 1 Solid EGFR DM1 SMCC No
IMGN529 ImmunoGen, Inc. 1 Hematological CD37 DM1 SMCC No
IMGN853,
mirvetuximab
soravtansine
ImmunoGen, Inc. 1 Solid FOLR1 DM4 Sulfo-SPDB Yes 6.0 ocular
toxicity [21]
LOP628 Novartis
Pharmaceuticals
1 Solid cKIT Maytansine Non-cleavable No
PCA062 Novartis
Pharmaceuticals
1 Solid p-Cadherin Unknown Unknown Unknown
MDX-1203,
BMS936561
Bristol-Myers
Squibb
1 Solid CD70 Duocarmycin VC Yes No MTD
reported,
neuropathy at
15 mg/kg [62]
MEDI-547,
MI-CP177
Medimmune
LLC
1 Solid EphA2 MMAF MC No
PF-06263507 Pfizer 1 Solid 5T4 MMAF MC No
PF-06647020 Pfizer 1 Solid Unknown Unknown Unknown Unknown
PF-06647263 Pfizer 1 Solid EphrinA Calicheamicin Hydrazone
acetyl
butyrate
Yes
PF-06664178 Pfizer 1 Solid Trop-2 Microtubule
inhibitor
Unknown Unknown
RG7450,
DSTP3086S
Genentech, Inc. 1 Solid STEAP1 MMAE VC Yes 2.4 [63] liver
toxicity
RG7458,
DMUC5754A
Genentech, Inc. 1 Solid MUC16 MMAE VC Yes 2.4 [27]
neutropenia
RG7598,
DFRF4539A
Genentech, Inc. 1 Hematological Unknown MMAE Unknown Unknown
SAR566658 Sanofi 1 Solid CA6 DM4 SPDB Yes 6.5 [64] ocular
toxicity,
diarrhea
SGN-CD19A Seattle
Genetics, Inc.
1 Hematological CD19 MMAF MC No Not yet
reached at
6 mg/kg
SGN-CD33A Seattle
Genetics, Inc.
1 Hematological CD33 PBD VA Yes Neutropenia
Current Opinion in Immunology 2016, 40:14–23 www.sciencedirect.com
Antibody-drug conjugate-based therapeutic approaches de Goeij and Lambert 17
Table 1 (Continued )
Drug names Sponsor Phase Indication Target Payload Linker Bystander MTD mg/kg
SGN-CD70A Seattle
Genetics, Inc.
1 Solid CD70 PBD VA Yes
SGN-LIV1A Seattle
Genetics, Inc.
1 Solid LIV1 MMAE VC Yes
SYD985,
Trastuzumab
vc-seco DUBA
Synthon BV 1 Solid HER2 Duocarmycin VC Yes
a No severe dose-limiting toxicity found, but two of seven evaluable patients had prolonged drug-related neutropenia after 9 mg/m2 treatment.
TBD, to be determined; MTD, maximum tolerated dose; DLT, dose-limiting toxicity; VC, valine-citrulline; VA, valine-alanine; MC, maleimidocaproyl
linker; SMCC, N-succinimidyl 4-(N-maleimidomethyl)cyclohexane-1 carboxylate; SPDB, N-succinimidyl 4-(2-pyridyldithio)butyrate; SPP, N-succi-
nimidyl 4-(2-pyridyldithio)pentanoate; sulfo-SPDB, N-succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate; CL2A, maleimido-[short PEG]-Lys-
PABOCO-20-O.emtansine induced tumor regression at dose levels at or
above 3 mg/kg, but more potent efficacy was observed at
15 mg/kg [13,14]. This suggests that at the clinically
administered dose, ado-trastuzumab emtansine may not
exert its maximal potential anti-tumor effect. Likewise,
brentuximab vedotin has an MTD of 1.8 mg/kg in
humans [9], while in preclinical models of Hodgkin
lymphoma, the lowest dose that induced partial tumor
regression was generally about 1 mg/kg dose [15], sug-
gesting that the therapeutic index of brentuximab vedo-
tin is fairly narrow. Other examples can be drawn
from compounds in development. For example,Figure 1
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that targets GPNMB, showed modest clinical activity
in humans at the MTD of 1.9 mg/kg [16]. In preclinical
models of melanoma CR011-vcMMAE induced com-
plete tumor regression upon treatment with 2.5 mg/kg
ADC, but the 1.25 mg/kg dose showed only modest
activity [17]. Another vcMMAE conjugated antibody,
MLN0264 (indusatumab vedotin) that targets guanylyl
cyclase C (GCC) positive tumors, has an MTD of 1.8 mg/
kg in humans [10]. Yet it has been described to show
significantly better inhibition of GCC-positive xenografts
at a dose of 7.5 mg/kg compared to 3.75 mg/kg dose [18].PayloadLinker
NH
OH2Ne.g.
O
O
N
H
H
N
Stability in circulation
Conjugation site
Cleavable or non-cleavable
Mechanism of payload
release
Bystander effect
Multidrug resistance
• On target cytotoxicity
(potency)
Off target cytotoxicity
Bystander effect
Efficacy against nonprolif-
erating cells
Multidrug resistance
Amenable to linker 
chemistry
Pharmacokinetics free drug
•
•
•
•
•
•
•
•
•
•
•
•
Current Opinion in Immunology
is driven by selection of the right combination of tumor antigen,
n level of ADC targets on tumor cells and healthy tissue as well as the
r selection of the most optimal linker-drug combination [65,66,67].
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tumor models but their therapeutic window in the clinic is
narrow and dosing regimens seem hampered by dose-
limiting toxicities that could not always be predicted
based on data from preclinical models. This lack of
predictability is especially illustrated by the fact that
non-cleavable auristatin and maytansine conjugates are
virtually devoid of toxicity in preclinical models at doses
equivalent to the MTD for cleavable auristatin and
maytansine conjugates. Yet in the clinic they induce
toxicity at doses that are the same or even lower as
compared to their cleavable-linked counterparts
[8,13,19]. In addition several other factors make it difficult
to extrapolate preclinical data to the clinic, such as
differences in proliferation rates, tumor burden, multi-
drug-resistance pumps and target-mediated clearance.
For most ADCs currently in clinical development, dose-
limiting toxicities appear to be unrelated to the targeted
antigen. For example reversible ocular toxicity specific to
the cornea has been reported as the dose-limiting toxicity
(DLT) for disulfide-linked DM4-conjugated antibodies
targeting antigens as diverse as CD19 [7], CanAg [20],
folate receptor alpha [21] and mesothelin [22], none of
which are thought to have significant expression in the eye.
Similar toxicity has been reported for all ADCs conjugated
with MMAF via an uncleavable linker [7,23]. By contrast,
no ocular toxicity has been described for a MUC16 ADC
conjugated with vcMMAE, despite the fact that MUC16
expression has been described in human ocular surface
epithelia [24]. In fact, most, if not all, ADCs made with
vcMMAE have a similar toxicity profile, with acute neu-
tropenia and neuropathy (upon repeated dosing) being the
dose-limiting adverse events, irrespective of the target
antigen, CD30 [9], PSMA [25], gpNMB [16], NaPi2b
[26], MUC16 [27], GCC [10], CD22 [28] and CD79b
[29]. The fact that normal tissue expression often does
not drive ADC toxicity is further illustrated by clinical
experience with ado-trastuzumab emtansine. HER2 ex-
pression has been described in various healthy organs such
as heart, skin and epithelial cells of the gastrointestinal tract
[30]. Trastuzumab, the unconjugated antibody counterpart
of ado-trastuzumab emtansine, has been reported to in-
duce cardiotoxicity in combination with chemotherapy
[31], which is thought to be related to HER2 expression
in the heart. By contrast, the DLT of ado-trastuzumab
emtansine is reversible thrombocytopenia, thought to be
an off-target toxicity, with no clinically significant toxicity
reported in heart, skin or epithelial tissue [6].
However, for some ADCs, certain toxicities observed in
clinical trials appear to be on-target effects. For example,
in the case of glembatumumab vedotin, development of
skin rash was one of the observed dose-limiting toxicities
[16], which is probably due to membrane expression of
gpNMB in epithelial cells of the skin [32]. Previously,
development of an ADC directed against CD44v6Current Opinion in Immunology 2016, 40:14–23 (bivatuzumab mertansine) was discontinued due to se-
vere skin toxicity [33], which was also linked to high
CD44v6 expression in the skin.
In general, antigens that are internalized well, with low
expression on normal tissue and high expression on tumors
are preferred for an ADC approach. However, the results of
clinical trials indicate that it may be difficult to predict the
toxicity profile based on target expression in healthy tissue.
Therefore selection of antigens that are not particularly
tumor specific, but highly overexpressed in tumors may, in
certain circumstances, increase the efficacy of tubulin
based ADCs without changing the MTD.
ADCs and the immune system
The mechanism behind the off-target toxicity of ADCs is
poorly understood. Neutropenia and thrombocytopenia
could be explained by cytotoxicity of the free payload
after processing of the linker-drug by the targeted cells or
in the tumor microenvironment [34]. Alternatively, up-
take and processing of ADCs by Fcg-receptor bearing
cells has been proposed as a potential mechanism of
toxicity (Figure 2). For example, FcgRIIa binding has
been proposed to be involved in the development of
thrombocytopenia induced by ado-trastuzumab emtan-
sine. Megakaryocytes showed uptake of trastuzumab and
ado-trastuzumab emtansine which could be blocked with
an FcgRIIa blocking antibody. The uptake of ado-tras-
tuzumab emtansine as well as an isotype control ADC by
megakaryocytes resulted in cytotoxicity, which was not
observed with unconjugated trastuzumab [35]. However,
these experiments were not done in the presence of non-
immune human IgG at levels comparable to those found
in human blood, so it is also possible that non-specific
mechanisms such as pinocytosis may contribute to uptake
of ADC by antigen-negative hematological cells in vivo at
the relatively high initial concentrations of ADC in blood
plasma after administration (0.1 mg/mL).
Whereas, on the one hand interactions with Fcg-receptors
have been implicated in toxicity of ADCs, on the other
hand at least one ADC with enhanced Fc-receptor bind-
ing has entered clinical development. J6M0-mcMMAF
(GSK2857916), an ADC targeting the B-cell maturation
antigen (BCMA) that is selectively expressed on multiple
myeloma (MM) cells, was able to eliminate MM tumors
in subcutaneous and disseminated MM models. The
investigators used a defucosylated antibody with en-
hanced affinity for FcgRIIIa expressing immune cells.
J6M0-mcMMAF induced antibody-dependent cell-me-
diated cytotoxicity (ADCC) and macrophage-mediated
phagocytosis in vitro and enhanced macrophage infiltra-
tion in bone marrow tissues from SCID mice bearing
MM1Sluc tumors [36].
Just as the role of IgG–FcgR interactions to toxicity is
unknown, it is unclear to what extent FcgR-mediatedwww.sciencedirect.com
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Figure 2
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Overview of potential mechanism of toxicity induced by ADCs and strategies to minimize these toxic effects.effector functions contribute to the clinical efficacy of
ADCs. Generally, antibody-mediated effector functions
were similar between the naked antibody and the corre-
sponding ADC. Considering the two approved ADCs,
the capacity of trastuzumab to induce ADCC was not
affected through conjugation with DM1 [37], while
brentuximab has been described to induce antibody-
dependent cellular phagocytosis in vivo, which is be-
lieved to contribute to the potent anti-tumor efficacy
observed for brentuximab vedotin [38]. Although in the
latter case, the naked anti-CD30 antibody had no clinical
activity [39], it may be that Fc-receptor-mediated anti-
tumor activity compliments payload delivery by the
ADC, for increased clinical benefit.
More recently, ADCs based on auristatins have been
suggested to stimulate a tumor-specific adaptive immune
response [40]. Using fully immunocompetent mice with
syngeneic RMAThy1.1 tumors, it was demonstrated that
MMAE-coupled ADCs can induce dendritic cell (DC)
homing to tumor draining lymph nodes. Analysis ofwww.sciencedirect.com PBMCs from Hodgkin lymphoma patients obtained be-
fore and after treatment with brentuximab vedotin
showed activation of adaptive immunity as indicated
by a significant decrease in the number of T-regulatory
cells and increased activation of peripheral DCs and B-
cells. These effects were not dependent on cytotoxicity
towards the tumor cells, indicating a direct effect on DCs.
Furthermore it was demonstrated that combined treat-
ment of dolastatins with immune modulating antibodies
targeting CTLA-4 and PD-1 resulted in slower outgrowth
of MC38 tumors and altered ratio between regulatory and
effector T-cells. These observations were also extended
to maytansinoids and ado-trastuzumab emtansine [41].
The ability of chemotherapeutic agents to stimulate
immunological cell death has been widely appreciated
[42]. However, the potential clinical benefit of this effect
may be limited during classical chemotherapy treatment
regimens, that are associated with major immunosuppres-
sive side effects [43]. The enhanced tumor-specificity of
ADCs, however, may allow for reduced immunosuppres-
sive side effects while increasing anti-tumor immunity.Current Opinion in Immunology 2016, 40:14–23
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The clinical success of maytansinoid-based and aurista-
tin-based ADCs has sparked increased research into
evaluation of even more potent cytotoxic compounds
having different cell-killing mechanisms for utilization
as ADC payloads. Most such research is with DNA-
damaging agents such as pyrrolobenzodiazepine (PBD)
dimers [44], calicheamicins, duocarmycins [45] and indo-
linobenzodiazepine dimers [46]. PBD dimers have shown
promising cytotoxicity and displayed anti-tumor activity
at 10 fold lower concentration as compared to auristatins
and maytansinoids. PBD dimers block cancer cell division
by binding in the minor groove of DNA and crosslinking
opposing strands of DNA without distorting the DNA
helix, thus potentially avoiding DNA-repair mechanisms
and emergent drug resistance [47]. Recently, several
ADCs conjugated with PBD dimers have entered clinical
development. SGN-CD33A, a humanized anti-CD33 an-
tibody conjugated to a PBD dimer via a protease cleav-
able valine-alanine dipeptide linker is being tested in
acute myeloid leukemia [44]. SGN-CD33A showed im-
pressive anti-tumor activity in xenograft models at doses
as low as 0.1 mg/kg of ADC. This activity was dependent
on the presence of cell surface antigen, although no
correlation was observed between degree of efficacy
and the levels of CD33 on the cell surface [44]. The
same PBD-linker format was used to develop a CD70
ADC (SGN-CD70A), for the treatment of patients with
renal cell carcinoma (RCC) and non-Hodgkin lymphoma
(NHL). Here too, the ADC showed impressive anti-
tumor activity in preclinical models dosed at 0.1 and
0.3 mg/kg of ADC [48]. The potential of PBD dimers
to target cell populations that are drug-resistant has been
demonstrated with rovalpituzumab tesirine, an anti-
DLL3 antibody conjugated to a PBD dimer. In patient
derived xenograft models of small cell lung cancer
(SCLC) the ADC was able to eradicate DLL3-positive
drug-resistant tumor-initiating cells [49]. Moreover, a
phase I study in patients with relapsed and refractory
SCLC demonstrated that at the MTD of 0.2 mg/kg,
rovalpituzumab tesirine was able to induce partial
responses in 7 out of 16 patients and stable disease in
a further 8 patients [50].
Recently, SYD985, a HER2 ADC conjugated with the
cleavable linker-duocarmycin analog, vc-seco-DUBA, en-
tered clinical development. The ADC was able to inhibit
growth of low HER2 expressing patient derived xenografts
(PDX) at a single dose of 1 mg/kg [51]. This effect may
even be underestimated because vc-seco-DUBA conjugat-
ed ADCs have poor PK properties in mouse plasma, due to
presence of mouse-specific carboxylesterase (CES1c)
which can release the payload from the ADC [51]. In
human plasma, vc-seco-DUBA conjugated ADCs are quite
stable. However, once released from the ADC, the active
compound DUBA is rapidly degraded with a half-life of
approximately 1 h. Although this seems unfavorable fromCurrent Opinion in Immunology 2016, 40:14–23 an efficacy point of view, the rapid degradation of DUBA
may also translate to lower systemic toxicity and allow for
higher dosing in clinical testing [45].
These exciting preclinical data and emerging clinical
results with ADCs containing potent DNA-targeting pay-
loads, both PBD dimers and duocarmycin based com-
pounds, demonstrate that these ADCs are capable of
inhibiting tumor growth at relatively low doses and re-
quire only modest expression of the targeted antigen.
Studies addressing the safety and establishing the MTD
will determine whether these extremely potent toxins can
contribute to increasing the therapeutic index of ADCs
towards such targets.
Summary
The increased clinical experience with tubulin-based
ADCs and emerging clinical data with ADCs containing
DNA-targeting payloads, help us to better understand the
target requirements needed for successful ADC design.
The relative lack of immunosuppressive side effects of
many ADCs, suggests that a potential component of the
clinical benefit obtained with some ADCs may be the
engagement of the immune system. There is still much to
learn about the clinical application of ADC technologies,
but the success of brentuximab vedotin and ado-trastu-
zumab emtansine have emboldened research into im-
proved cancer treatments utilizing ADCs that has the
prospect for improved outcomes for many cancer patients.
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